Intralytix, Inc. is focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings. Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are natural enemies of disease causing bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting the rest of the microbiome, ensuring an unprecedented level of safety for an antimicrobial.
bacteriophage depiction
bacteriophage depiction
bacteriophage depiction
bacteriophage depiction
bacteriophage depiction
bacteriophage depiction
Intralytix Launches Phase 1/2a Phage Therapy Trial of Its VRELysin™ Phage Preparation, to Assess Safety and Efficacy in Healthy and VRE-Colonized Subjects
09/12/2023 2 weeks ago
Columbia, Maryland - September 12, 2023 - Intralytix, Inc. today announced the launch of a Phase 1/2a clinical trial to assess the safety and efficacy of its phage therapy product VRELysin™ in significantly reducing or eliminating vancomycin-resistant enterococci (VRE) levels in the human gastrointestinal tract.
Intralytix's EcoActive Phase 1/2a Phage Trial Begins Enrollment at Johns Hopkins University in the Baltimore, Maryland Metro Area
08/01/2023 1 month ago
Intralytix, Inc. announced today that the clinical trial “A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia coli (AIEC) in patients with inactive Crohn’s disease (CD),” will begin enrolling at the Johns Hopkins University (JHU) at various locations throughout the Baltimore metro area in Maryland (USA).
Full Enrollment of Phase 1 Safety Trial Achieved of Intralytix Phage Product to Prevent Illness Caused by Shigella
03/24/2023 6 months ago
Intralytix, Inc. today announced successful, full enrollment of its Phase 1 clinical trial at the University of Maryland’s School of Medicine (UMSOM) in Baltimore under the direction of Dr. Wilbur Chen, Professor of Medicine and Chief of Adult Clinical Studies at UMSOM’s Center for Vaccine Development and Global Health (CVD).

What is a bacteriophage?

A bacteriophage (also known as a phage) is a type of virus that infects and replicates within bacteria. Bacteriophages are composed of a nucleic acid molecule (DNA or RNA) surrounded by a protein coat, and they are specific to certain types of bacteria.

Bacteriophages are found in many different environments, including soil, water, and the human gut. They play a significant role in the natural balance of bacteria in these environments and can be used as a tool to control bacterial infections in humans.

How do bacteriophages work?

Bacteriophages work by attaching to the surface of a bacterial cell and injecting their genetic material into the cell. The phage's genetic material then takes over the machinery of the bacterial cell, replicating itself and eventually causing the cell to burst and release new phages. This process is known as the lytic cycle, and it can lead to the rapid destruction of the bacterial population.

Bacteriophages have been studied for their potential use as antimicrobial agents, and some have been developed into phage therapies for the treatment of bacterial infections that are resistant to traditional antibiotics.